cci 103f profile

CCI 103F: hexafluorinated nitroimidazole; hypoxic cell marker; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	128527
SCHEMBL ID	6946434
MeSH ID	M0142903

Synonym
cci 103f
1-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)-3-(2-nitroimidazol-1-yl)propan-2-ol
1h-imidazole-1-ethanol, 2-nitro-alpha-((2,2,2-trifluoro-1-(trifluoromethyl)ethoxy)methyl)-
104290-39-3
cci-103f
unii-2iw6lax4hz
2iw6lax4hz ,
1h-imidazole-1-ethanol, 2-nitro-.alpha.-((2,2,2-trifluoro-1-(trifluoromethyl)ethoxy)methyl)-
SCHEMBL6946434
3-(1,1,1,3,3,3-hexafluoroprop-2-oxy)-1-(2-nitroimidazol-1-yl)propan-2-ol
rwmnrehjlvxwrn-uhfffaoysa-n
Q27254798
1-[(1,1,1,3,3,3-hexafluoropropan-2-yl)oxy]-3-(2-nitro-1h-imidazol-1-yl)propan-2-ol
DTXSID70908903
1h-imidazole-1-ethanol, 2-nitro-.alpha.-[[2,2,2-trifluoro-1-(trifluoromethyl)ethoxy]methyl]-

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4 (16.67)	18.7374
1990's	12 (50.00)	18.2507
2000's	6 (25.00)	29.6817
2010's	2 (8.33)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	24 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
niacinamide nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.	2.02	1	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
bromodeoxyuridine Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.	2.02	1	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent
azomycin azomycin: RN given refers to parent cpd with specified locant; structure	4.51	24	C-nitro compound; imidazoles	antitubercular agent
gadolinium Gadolinium: An element of the rare earth family of metals. It has the atomic symbol Gd, atomic number 64, and atomic weight 157.25. Its oxide is used in the control rods of some nuclear reactors.	2.05	1	f-block element atom; lanthanoid atom
misonidazole Misonidazole: A nitroimidazole that sensitizes normally radio-resistant hypoxic cells to radiation. It may also be directly cytotoxic to hypoxic cells and has been proposed as an antineoplastic.	2.37	2
pimonidazole pimonidazole: structure given in first source	3.53	8
carbogen carbogen: mixture of 95% O2 & 5% CO2	2.72	3
fluoromisonidazole [no description available]	1.97	1
hoe 33342 bisbenzimide ethoxide trihydrochloride: benzimidazole fluorescent dye	2.71	3

Condition	Relationship Strength	Studies
Cancer of Pituitary [description not available]	2.08	1
Adenoma, Prolactin-Secreting, Pituitary [description not available]	2.08	1
Pituitary Neoplasms Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.	2.08	1
Adenocarcinoma, Basal Cell [description not available]	2.91	4
Cancer of Lung [description not available]	2.05	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.91	4
Lung Neoplasms Tumors or cancer of the LUNG.	2.05	1
Carcinoma, Epidermoid [description not available]	2.7	3
Cancer of Cervix [description not available]	2.42	2
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.7	3
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	2.42	2
Cancer of Colon [description not available]	2.42	2
Colonic Neoplasms Tumors or cancer of the COLON.	2.42	2
Benign Neoplasms [description not available]	3.6	9
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.6	9
Canine Diseases [description not available]	3.24	6
Carcinoma, Basal Cell, Pigmented [description not available]	1.98	1
Carcinoma, Basal Cell A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)	1.98	1
Experimental Neoplasms [description not available]	3.07	5
Anoxemia [description not available]	1.98	1
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	1.98	1
Atypical Lipomatous Tumor [description not available]	1.98	1
Synovioma [description not available]	1.98	1
Liposarcoma A malignant tumor derived from primitive or embryonal lipoblastic cells. It may be composed of well-differentiated fat cells or may be dedifferentiated: myxoid (LIPOSARCOMA, MYXOID), round-celled, or pleomorphic, usually in association with a rich network of capillaries. Recurrences are common and dedifferentiated liposarcomas metastasize to the lungs or serosal surfaces. (From Dorland, 27th ed; Stedman, 25th ed)	1.98	1
Sarcoma, Synovial A malignant neoplasm arising from tenosynovial tissue of the joints and in synovial cells of tendons and bursae. The legs are the most common site, but the tumor can occur in the abdominal wall and other trunk muscles. There are two recognized types: the monophasic (characterized by sheaths of monotonous spindle cells) and the biphasic (characterized by slit-like spaces or clefts within the tumor, lined by cuboidal or tall columnar epithelial cells). These sarcomas occur most commonly in the second and fourth decades of life. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1363)	1.98	1
Cancer of Prostate [description not available]	2.38	2
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.38	2
Carcinoma 256, Walker A transplantable carcinoma of the rat that originally appeared spontaneously in the mammary gland of a pregnant albino rat, and which now resembles a carcinoma in young transplants and a sarcoma in older transplants. (Stedman, 25th ed)	2.38	2
EHS Tumor [description not available]	1.97	1
Experimental Mammary Neoplasms [description not available]	1.97	1

cci 103f

Description

Cross-References

Synonyms (15)

Research

Studies (24)

Study Types

cci 103f

Description

Cross-References

Synonyms (15)

Research

Studies (24)

Study Types

Related Drugs (9)

Related Conditions (30)